X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with Merck Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs MERCK LTD - Comparison Results

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA MERCK LTD SHASUN PHARMA/
MERCK LTD
 
P/E (TTM) x 123.9 45.5 272.5% View Chart
P/BV x 8.5 6.9 124.2% View Chart
Dividend Yield % 0.2 0.4 56.6%  

Financials

 SHASUN PHARMA   MERCK LTD
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
MERCK LTD
Dec-16
SHASUN PHARMA/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs941,060 8.9%   
Low Rs46623 7.3%   
Sales per share (Unadj.) Rs214.2632.4 33.9%  
Earnings per share (Unadj.) Rs5.345.7 11.7%  
Cash flow per share (Unadj.) Rs15.862.3 25.4%  
Dividends per share (Unadj.) Rs1.0011.00 9.1%  
Dividend yield (eoy) %1.41.3 109.4%  
Book value per share (Unadj.) Rs53.3388.8 13.7%  
Shares outstanding (eoy) m56.6216.60 341.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.31.3 24.5%   
Avg P/E ratio x13.118.4 71.2%  
P/CF ratio (eoy) x4.413.5 32.7%  
Price / Book Value ratio x1.32.2 60.6%  
Dividend payout %18.724.1 77.9%   
Avg Mkt Cap Rs m3,95813,969 28.3%   
No. of employees `000NA1.6 0.0%   
Total wages/salary Rs m2,1641,487 145.5%   
Avg. sales/employee Rs ThNM6,631.9-  
Avg. wages/employee Rs ThNM939.2-  
Avg. net profit/employee Rs ThNM479.4-  
INCOME DATA
Net Sales Rs m12,12710,498 115.5%  
Other income Rs m229242 94.6%   
Total revenues Rs m12,35610,741 115.0%   
Gross profit Rs m1,0091,135 88.9%  
Depreciation Rs m594276 215.5%   
Interest Rs m4150-   
Profit before tax Rs m2301,102 20.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-73343 -21.2%   
Profit after tax Rs m302759 39.8%  
Gross profit margin %8.310.8 76.9%  
Effective tax rate %-31.731.1 -101.6%   
Net profit margin %2.57.2 34.5%  
BALANCE SHEET DATA
Current assets Rs m6,8846,410 107.4%   
Current liabilities Rs m8,4568,828 95.8%   
Net working cap to sales %-13.0-23.0 56.2%  
Current ratio x0.80.7 112.1%  
Inventory Days Days6258 106.8%  
Debtors Days Days10838 280.2%  
Net fixed assets Rs m4,9701,406 353.4%   
Share capital Rs m113166 68.3%   
"Free" reserves Rs m2,8756,286 45.7%   
Net worth Rs m3,0206,455 46.8%   
Long term debt Rs m1,8170-   
Total assets Rs m13,3478,828 151.2%  
Interest coverage x1.6NM-  
Debt to equity ratio x0.60-  
Sales to assets ratio x0.91.2 76.4%   
Return on assets %5.48.6 62.5%  
Return on equity %10.011.8 85.1%  
Return on capital %13.317.1 78.0%  
Exports to sales %46.48.3 559.8%   
Imports to sales %14.221.0 67.7%   
Exports (fob) Rs m5,622869 646.6%   
Imports (cif) Rs m1,7282,209 78.2%   
Fx inflow Rs m5,843959 609.4%   
Fx outflow Rs m2,1732,612 83.2%   
Net fx Rs m3,669-1,653 -222.0%   
CASH FLOW
From Operations Rs m3981,070 37.1%  
From Investments Rs m-1,635-750 218.1%  
From Financial Activity Rs m1,309-150 -873.6%  
Net Cashflow Rs m71171 41.7%  

Share Holding

Indian Promoters % 39.2 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 3.6 18.2 19.8%  
FIIs % 17.6 1.0 1,760.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 29.1 136.1%  
Shareholders   20,750 28,591 72.6%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   IPCA LABS  NOVARTIS  DR. DATSONS LABS  ORCHID PHARMA LTD  SANOFI INDIA  

Compare SHASUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Marginally Lower; FMCG & IT Stocks Witness Losses(Closing)

After opening the day on a positive note today, Indian share markets witnessed losses thereafter and ended their trading session marginally lower.

Related Views on News

MERCK LTD Announces Quarterly Results (1QFY19); Net Profit Up 63.1% (Quarterly Result Update)

Aug 8, 2018 | Updated on Aug 8, 2018

For the quarter ended June 2018, MERCK LTD has posted a net profit of Rs 328 m (up 63.1% YoY). Sales on the other hand came in at Rs 2 bn (down 17.1% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

MERCK LTD Announces Quarterly Results (4QFY18); Net Profit Up 53.2% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, MERCK LTD has posted a net profit of Rs 227 m (up 53.2% YoY). Sales on the other hand came in at Rs 3 bn (up 27.1% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 8-QTR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS